Centessa Pharmaceuticals plc announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors. LB101, a conditionally tetravalent PD-L1xCD47 LockBody® bispecific monoclonal antibody targeting solid tumors, is the first product candidate developed using the Company's proprietary LockBody technology which is designed to selectively drive potent effector function activity, such as CD47, in the tumor microenvironment (TME) while avoiding systemic toxicity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.93 USD | +4.09% | +1.43% | +24.75% |
06-21 | Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $11 From $8, Maintains Equalweight Rating | MT |
06-10 | Centessa Pharmaceuticals Appoints John Crowley as CFO | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.75% | 1.08B | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- CNTA Stock
- News Centessa Pharmaceuticals plc
- Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors